Advancing research, development and therapy for ALS and additional CNS indications.NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.